Late‑breaking data at ASH showed striking efficacy for bispecific and in‑vivo CAR‑T approaches in multiple myeloma. The MajesTEC‑3 trial presented an 83.4% three‑year progression‑free survival for the teclistamab plus daratumumab combination versus standard care, a large treatment effect reported as potentially practice‑changing. The result was presented during a late‑breaker session at the American Society of Hematology. Separately, Kelonia reported early in‑vivo CAR‑T readouts showing tumor control signals in multiple myeloma, adding momentum to the growing field of off‑the‑shelf or in‑body CAR‑T delivery strategies. Companies and clinicians framed these results as evidence that bispecific antibodies and novel CAR‑T modalities can produce deep, durable responses. The data will influence development priorities, investigator trial designs and commercial positioning as stakeholders weigh safety profiles, manufacturing complexity and sequencing against existing autologous CAR‑T and antibody options.